Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

114.52 -0.03 (-0.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
64 65 Next >
GILEAD SCIENCES INC (NASDAQ:GILD): A Prime Value Investing Candidate with Strong Fundamentals
Gilead Sciences (GILD) is a strong value investing candidate, trading at a significant discount with high profitability, solid financial health, and positive growth prospects. 
Via Chartmill
SLB, Apple, Nvidia, Merck, Gilead Sciences: What Sparked Heavy After-Hours Trading In These 5 Stocks?
Via Stocktwits
Tariffs Cast a Long Shadow: Consumer Prices Soar Across Essential Goods
American households are bracing for a significant financial hit as a wave of tariff-induced inflation sweeps across critical consumer goods and services. From the family car to essential baby products,... 
Via MarketMinute
Topics Economy Government World Trade
Why Is Novo Nordisk’s Stock Rising Premarket Today?
Via Stocktwits
Xilio Stock Jumps 8% On Cancer Drug Data; Gilead Boost Extends Cash Runway Into 2027 — Retail Says Stock Undervalued
Via Stocktwits
Cooling Wages Cast a Shadow: Economic Recovery at Risk as Consumer Spending Slows
The American economy is facing a new headwind as weakening wage growth begins to temper consumer spending, raising concerns about the pace and sustainability of the broader economic recovery. Recent... 
Via MarketMinute
Topics Credit Cards Economy Supply Chain
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at LSX World Congress 2025
Via Investor Brand Network
Topics Intellectual Property
Wolfspeed, Nvidia, Gilead, SLBM, Corning: What Sparked Heavy After-Hours Trading In These 5 Stocks?
On Monday, the tech-heavy Nasdaq Composite climbed to a new high despite the ongoing uncertainty regarding the state of the U.S. economy and the rate outlook. 
Via Stocktwits
Topics Artificial Intelligence Bankruptcy Economy
Global Economic Slowdown and Escalating Tariffs: A Looming Threat to Market Growth
The global economy is currently grappling with a projected deceleration in GDP growth, a situation severely exacerbated by an unprecedented escalation of U.S. tariffs. These twin forces are creating a... 
Via MarketMinute
Topics Economy Supply Chain World Trade
2024 R&D Spending and Intensity Benchmarks
Via PRLog
Topics Supply Chain
Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy
From Gilead Sciences, Inc.
Via Business Wire
1 Healthcare Stock to Consider Right Now and 2 We Question
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
Beating The September Curse–These 10 Stocks Shine While The S&P 500 Stumbles
September is historically the worst month for stocks, but these 10 S&P 500 companies have consistently delivered gains. 
Via Benzinga
Topics Stocks
Veeva Makes A Bearish Move On One Pockmark In Its Quarterly Report
The company beat second-quarter expectations, with the exception of one key metric. 
Via Investor's Business Daily
Eli Lilly Scores Another Weight-Loss Win; Viking, Novo Stocks Slump
Eli Lilly said Tuesday it will soon ask global regulators to approve its weight-loss pill following a third successful test. 
Via Investor's Business Daily
Gilead Sciences' 99.9% Effective HIV Treatment Notches Another Win
The drug is soon to launch in Europe with a new name and a big potential market. 
Via Investor's Business Daily
European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
Options Corner: Why The Market Could Be Prescribing A Bull Call Spread For Gilead Sciences
While Gilead Sciences posted a strong Q2 earnings print, GILD stock saw profit-taking. Here's why the red ink could be an opportunity. 
Via Benzinga
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Drug Tariffs Finally Land. Why Pharma Stocks Are Breathing Easy.
The tariffs will impact products imported from Europe, the Trump administration said late Thursday. 
Via Investor's Business Daily
Topics ETFs Government Intellectual Property
Market Monitor News August 22 BMO - Coty Crumbles, Powell Looms: Wall Street Cautious Amid Mixed Signals
Markets dipped Thursday as Coty issued a dismal forecast, Gilead faced headwinds with its new HIV drug, and investors turned cautious ahead of Fed Chair Powell’s Jackson Hole speech. Solid PMI data... 
Via Chartmill
Topics Economy
Gildea's Kite Pharma Just Acquired Interius—$350 Million Move Shakes Up Cancer Therapy
Kite Pharma is acquiring Interius BioTherapeutics for $350 million, adding in vivo CAR T technology that could simplify treatment and expand patient access. 
Via Benzinga
Why Gilead Sciences (GILD) Shares Are Sliding Today
Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) fell 3.5% in the morning session after reports that CVS Health will not be adding the company's new HIV prevention drug, Yeztugo, to... 
Via StockStory
Topics Earnings
These S&P500 stocks are gapping in today's session
Curious about the market action on Thursday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
Gilead Topples On A Surprise Setback For Its 99.9% Effective HIV Drug
Insurance coverage is key for any new drug. But it's looking tenuous for Gilead Sciences' newest HIV prevention drug. 
Via Investor's Business Daily
CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans
CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties. 
Via Benzinga
Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
64 65 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.